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Abstract
Extracorporeal assist systems for respiratory and circulatory failure are increasingly used in intensive care medicine. 
Important technical innovations over the past years have resulted in improved biocompatibility and, consequently, 
reduced complication rates. Extracorporeal membrane oxygenation (ECMO) technology experienced a surge of use 
during the influenza A (H1N1) pandemic, but transport of unstable patients with life-threatening ARDS is still hazardous. 
We describe the first successful application of a newly developed, compact and easily portable ECMO device in a patient 
with severe ARDS due to influenza A (H1N1). Support with the miniaturized ECMO resulted in immediate improvement 
of gas exchange and a highly protective ventilation. Inspiratory pressure was decreased from 40 to 29 cmH2O and tidal 
volume per kilogram of predicted bodyweight could be reduced from 6.5 to 3.3 mL.
Small and efficient heart-lung assist systems will become a tool of growing importance in intensive care medicine, both 
for profound respiratory and cardiac failure in the future. The reduced weight and compact design of the device greatly 
facilitates transport and handling of unstable patients on ECMO.
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Introduction
The first successful application of extracorporeal mem-
brane oxygenation (ECMO) for lung failure in a trauma 
patient was published in 19721. Important technical 
innovations in recent years have led to an increasing use 
of extracorporeal devices to support circulatory and pul-
monary function. In 2009, a randomized trial in adult 
patients with acute respiratory distress syndrome (ARDS) 
treated with ECMO indicated a significantly improved 
survival without disability compared to conventional 
ventilation support2. Transport of patients on ECMO 
from referring centres had not been possible in this trial. 
Lately, the employment of ECMO to patients with influ-
enza A (H1N1)-associated respiratory failure showed an 
impressive overall survival3. Miniaturized devices for 
extracorporeal gas exchange showed reduced complica-
tion rates and allowed successful use of ECMO in patients 
with thrombocytopenia and risk of hemorrhage4.
We report on the worldwide first application in men 
of a new compact, portable ECMO device with inte-
grated pump and oxygenator in a patient with severe 
life-threatening ARDS due to influenza A (H1N1) in 
May 2010.
Case Report
A 30-year-old female patient (body mass index (BMI) 
49.5 kg/m²) presented to another hospital with progres-
sive dyspnea and elevated temperature up to 40°C of five 
days’ duration. Her past history was unremarkable apart 
from asthma controlled with inhaled steroids. She was 
admitted to the intensive care unit and needed immedi-
ate intubation for worsening hypoxia. Her condition 
deteriorated rapidly and she was transferred to our cen-
ter the same night. On admission, the patient was in need 
of vasopressors and invasive mechanical ventilation, 
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with inspiratory pressures up to 47 cmH
2
O, severe respi-
ratory acidosis and marginal oxygenation at an FiO
2
 of 
1.0 (Table1). Inflammatory parameters (procalcitonin 
3.73 ng/mL, normal <0.1 ng/mL) and lactic dehydroge-
nase (LDH 1143 U/L, normal <247 U/L) were elevated; 
severe rhabdomyolysis was present (creatinine kinase 
9721 U/L, normal <167 U/L) with consequent acute 
renal failure. As stabilization with conventional methods 
was not possible, despite a trial to optimize mechanical 
ventilation for several hours, no improvement occurred 
on prone positioning or inhaled vasodilators and the 
chest X-ray indicated severe ARDS (Figure 1), we decided 
to use extracorporeal respiratory support to improve gas 
exchange and to avoid prolonged aggressive ventilation.
The right femoral and the right internal jugular veins 
were cannulated with a long 22-Fr cannula (Maquet-
Cardiopulmonary-AG, Hirrlingen, Germany) and a 
short 17-Fr cannula (NovaLung-GmbH, Talheim, 
Germany) in the Seldinger technique. Extracorporeal 
membrane oxygenation was achieved with the newly 
developed Cardiohelp (Maquet-Cardiopulmonary-AG, 
Hirrlingen, Germany), which has been used for the first 
time (Figure 2, during transport to the computerized 
tomography (CT) scan). This device has a gas exchange 
surface area of 1.8 m², a heat exchange surface area of 
0.4 m² and a priming volume of about 600 mL. The dif-
fusion membrane of the oxygenator is made of 
polymethylpentene and the system is heparin coated 
(Bioline Coating™) from tip to tip. After initiation of 
the extracorporeal support, invasiveness of mechanical 
ventilation could be decreased immediately; respiratory 
Table 1. Gas exchange parameters and respiratory settings before, during and after extracorporeal support
Pre  
ECMO
Day1 Day2 Day3 Day4 Day5 Day6 Day7 Day8 Day9 Day10 Day11 Day12 Post  
ECMO
FiO2 1.0 0.6 0.60 0.50 0.50 0.70 0.50 0.50 0.40 0.40 0.40 0.40 0.35 0.40
PaO2/FiO2 
(mmHg)
73 115 128 136 138 99 142 130 183 200 155 218 251 230
PaCO2 
(mmHg)
93 44 48 50 49 48 37 36 45 39 29 36 44 43
pH 7.07 7.39 7.37 7.38 7.39 7.40 7.48 7.49 7.43 7.45 7.56 7.47 7.39 7.35
Tidal Volume  
(mL)
352 180 287 194 208 307 250 337 400 344 535 276 395 540
TV/kg pred  
BW (mL)
5.9 3.0 4.8 3.2 3.5 5.1 4.2 5.6 6.7 5.7 8.9 4.6 6.6 9.0
Minute Volume  
(L/min)
8.5 2.5 5.3 2.6 2.7 5.0 4.2 4.7 5.5 12.2 16.0 7.0 9.2 10.6
PIP (cmH2O) 40 29 33 28 27 27 26 23 24 22 32 19 21 18
PEEP (cmH2O) 26 22 22 20 17 13 13 12 11 10 11 10 9 8
Norepinephrine  
(mcg/kg/min)
0.19 0.09 0.05 0.09 0.01 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
(FiO2 = fraction of inspired oxygen, TV = tidal volume, pred. BW = predicted bodyweight, PIP = positive end-inspiratory pressure, PEEP = positive 
end-expiratory pressure).
Figure 1. Chest X-ray after implementation of ECMO; 
backflow cannula in right internal jugular vein.
parameters before, during and after ECMO are pre-
sented in Table 1. The polymerase chain reaction (PCR) 
for Influenza A-H1N1-RNA5 proved to be positive in 
the bronchiolo-alveolar lavage (BAL) the same day (107 
copies) and therapy with oseltamivir 150 mg tid was 
started. After 10 days, the PCR-test was still positive 
(104 copies), but after 17 days it proved to be negative in 
the BAL.
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Further clinical course was complicated by a hemor-
rhage into the right thigh due to difficult cannulation, 
which was controlled conservatively with reduced 
heparin dosing and an intended activated partial throm-
boplastin time (aPTT) of 40–45 seconds. The maximum 
decrease of platelets from initial values was less than 20% 
during ECMO therapy (Table 2). After early tracheot-
omy, sedation was tapered and the patient was supported 
with neurally adjusted ventilatory assist (NAVA) in a 
highly protective mode. Due to reduced anticoagulation, 
the oxygenator had to be exchanged once after 1 week of 
therapy. This was accomplished in less than one minute, 
without deterioration of the patient during the exchange, 
as FiO
2
 was temporarily increased. Weaning from ECMO 
support was possible on the 12th day of ECMO treatment 
after first slowly reducing blood flow to 1.5 L/min and 
sweep gas flow to 1 L/min. Thereafter, sweep gas flow was 
paused for 1 hour and ECMO was removed, as the 
patient remained stable. Renal function returned after 
two weeks and the patient was discharged from the ICU 
after 21 days, with uneventful further recovery.
Discussion
Extracorporeal membrane oxygenation is becoming 
increasingly recognized as a potentially life-saving tech-
nique to secure vital gas transfer in life-threatening respi-
ratory failure. During the Influenza A-(H1N1) pandemic, 
intensivists throughout the world used ECMO for the 
most severe cases of viral pneumonia. ECMO not only 
secures gas transfer, but also allows highly protective 
ventilation. It can be assumed that, thereby, the magni-
tude of ventilator-induced lung injury will be reduced 
and time is gained for the diseased lung to heal.
Historic ECMO trials could not demonstrate a sig-
nificant reduction of mortality in adults6,7. This was 
mainly caused by the need for a pronounced systemic 
anticoagulation due to the large foreign surface of early 
devices, which resulted in severe bleeding complications. 
In contrast, modern devices are characterized by a largely 
improved biocompatibility, with reduced artificial sur-
faces, heparin coating, plasma-resistant gas exchange 
membranes and centrifugal pumps. The new Cardiohelp 
heart-lung assist system integrates all components of 
ECMO into one compact device which is portable with a 
weight of less than 13 kg. Therefore, intra-hospital 
(Figure 2) and inter-hospital transport is greatly facili-
tated. Transfer of patients to specialized centers with 
ECMO support, who would otherwise be too unstable 
for transport, is becoming increasingly important8. 
Figure 2. Patient on transport with portable miniaturized 
ECMO.
Table 2. ECMO settings, efficiency of gas transfer, and ECMO-related laboratory parameters before, during and after 
extracorporeal support
Pre  
ECMO
Day1 Day2 Day3 Day4 Day5 Day6 Day7 Day8 Day9 Day10 Day11 Day12 Post  
ECMO
Blood Flow  
(L/min)
2.0 2.0 2.7 2.5 2.6 2.4 2.2 2.0 1.9 1.9 1.8 1.5
Sweep Gas  
Flow (L/min)
5 5 7 10 12 6 9 5 5 5 6 1
rpm 1850 1855 2300 2300 2300 2300 2135 2135 2135 2136 1990 2015
O2 Transfer 
(mL/min)
130 114 148 122 117 139 114 90 116 114 85 67
CO2 Transfer 
(mL/min)
244 210 170 225 237 168 202 164 160 114 131 40
Platelets (/nl) 205 209 220 182 158 162 176 224 274 288 320 246 200 182
Free Hb (mg/L) 98 57 50 91 254 61 104 56
aPTT 39 60 42 43 44 50 47 55 43 36 38 29 30 31
(rpm = revolutions per minute, Free Hb = free hemoglobin (normal <20 mg/L), aPTT = activated partial thromboplastin time)
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With the new device, saturation of inflowing central 
venous blood, hemoglobin and hematocrit are 
recorded continuously. Thus, central venous satura-
tion presents information about swings in oxygen con-
sumption in the course of the disease. The online 
documentation of inflow pressure values, recorded 
with stop-cock-free pressure chips, is helpful with 
respect to the need of volume substitution to increase 
venous filling. Transmembrane pressures, acquired 
automatically, can be useful to guide the necessity of 
an oxygenator-exchange. 
Small and efficient heart-lung assist systems will 
probably become a tool of growing importance in inten-
sive care medicine in the future. Not only will they be 
applied in severe hypoxemic and/or hypercapnic respira-
tory failure to decrease aggressiveness of invasive ventila-
tion, but will also be used more often in circulatory 
failure. For cardiogenic shock and circulatory arrest 
unresponsive to conventional therapy, veno-arterial 
ECMO has been used successfully9,10. Pesenti and col-
leagues recently have been looking forward to further 
improvements in extracorporeal gas exchange technol-
ogy, which had undergone huge progress in the last 30 
years11. We believe this new device, whose first clinical 
application in the world has been described here, will 
pave the way for new developments.
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